https://pharminent.com/mahzi-lets-rare-disease-families-invest-in-its-gene-therapy/ 2026-07-13T20:40:24Z Pharminent en Mahzi Lets Rare-Disease Families Invest in Its Gene Therapy 2026-07-13T20:40:24Z Blog https://pharminent.com/rare-disease-gene-therapy/rare-disease-gene-therapy-digest-july-13-2026/ 2026-07-13T20:27:29Z Pharminent en Rare Disease & Gene Therapy Digest • July 13, 2026 2026-07-13T20:27:27Z Blog https://pharminent.com/fda-posts-14-new-rejection-letters-just-days-after-confirming-a-pause/ 2026-07-13T20:32:11Z Pharminent en FDA Posts 14 New Rejection Letters Just Days After Confirming a Pause 2026-07-13T19:54:21Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-july-13-2026/ 2026-07-13T16:07:21Z Pharminent en Strategic News Watch • July 13, 2026 2026-07-13T16:07:19Z Blog https://pharminent.com/fda-approves-msds-keytruda-combinations-for-mibc-2/ 2026-07-13T14:59:16Z Pharminent en FDA approves MSD's Keytruda combinations for MIBC 2026-07-13T08:31:27Z Blog https://pharminent.com/oncology/oncology-intelligence-digest-july-10-2026/ 2026-07-12T18:29:17Z Pharminent en Oncology Intelligence Digest • July 10, 2026 2026-07-12T18:29:15Z Blog